Lupus Science & Medicine

Integrated immune profiling identifies a coordinated T-cell activation and inflammatory signature in SLE

Introduction Patients with SLE have an increased risk of infections and infection-related mortality, which may be associated ...
Lupus Science & Medicine

Prevalence and clinical associations of cerebral atrophy in systemic lupus erythematosus

Objectives To determine the prevalence of cerebral atrophy in a multi-ethnic systemic lupus erythematosus (SLE) cohort and to ...
Lupus Science & Medicine

Harnessing AI and social media to understand real-world patient experiences in SLE

Objective To apply large language models (LLMs) to Reddit posts referencing SLE to identify patient-expressed unmet medical ...
Lupus Science & Medicine

International development of a lupus-specific instrument to assess cognitive symptoms in patients with SLE: Lupus Brain Fog Severity Scale (LBFSS) study

Introduction Cognitive symptoms such as ‘brain fog’ are frequent and disabling in patients with SLE. We aimed to develop and ...
lupus.bmj

13 Managing skin manifestations in SLE

Fumaric acid esters in cutaneous lupus erythematosus Fumaric acid esters (FAEs), established immunomodulatory agents in the treatment of psoriasis and multiple sclerosis, have been investigated for ...
lupus.bmj

Circulating kidney injury molecule-1 as a prognostic biomarker for long-term renal outcomes in lupus nephritis: a retrospective cohort study

Objective To determine whether circulating kidney injury molecule-1 (KIM-1) predicts long-term renal outcomes in lupus nephritis (LN), including relapse, progression to end-stage kidney disease (ESKD) ...
lupus.bmj

Unsupervised clustering of clinical and laboratory features of systemic lupus erythematosus: insights from a multicentre cohort

Objective This study explored the relationship between clinical phenotypes and immuno-molecular features of systemic lupus erythematosus (SLE) using unsupervised machine learning and multi-omics ...
lupus.bmj

Report of the inaugural Interferon Research Summit: interferon in inflammatory diseases

An international summit on interferon (IFN) in inflammatory diseases, held in Gaithersburg, Maryland, USA (4–5 May 2017), united 22 internationally renowned clinicians and scientists with backgrounds ...
lupus.bmj

PT2:06 Obinutuzumab induces histological remission and deep kidney parenchymal B-cell depletion in patients with lupus nephritis: exploratory analyses of the phase III regency ...

Objectives The REGENCY trial (NCT04221477) demonstrated superiority of obinutuzumab (OBI) plus standard therapy (+ST) vs placebo (PBO) +ST in achieving complete renal response (CRR) at Week 76 (W76) ...
lupus.bmj

Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered ...

Objective To determine the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneously administered mosunetuzumab, a CD20xCD3 T-cell-engaging bispecific antibody, in ...
lupus.bmj

Amelioration of renal injury by Qihuang Jianpi Zishen Granules in lupus mice is correlated with AMPK/ULK1-dependent modulation of macrophage polarisation

Objective To investigate the effects of Qihuang Jianpi Zishen Granules (QJZG) on renal injury in SLE mice, focusing on macrophage M1/M2 polarisation mediated by the AMPK/ULK1 signalling pathway.
lupus.bmj

Antiphospholipid syndrome in the paediatric population: performance of ACR-EULAR classification criteria in a controlled cohort

Introduction Antiphospholipid syndrome (APS) is a systemic autoimmune disorder marked by thrombotic and non-thrombotic manifestations. In children, diagnosis remains challenging due to lack of ...